Literature DB >> 8021787

Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study.

R Listernick1, J Charrow, M Greenwald, M Mets.   

Abstract

To assess the natural history of optic pathway tumors (OPT) in children with neurofibromatosis type 1 (NF-1), from January 1985 through May 1993 we performed a prospective, longitudinal study of OPT in an unselected population of children with NF-1. Of 227 children with NF-1 seen in a specialty clinic, 176 (77%) underwent neuroimaging. Children in whom tumors were identified were followed closely by both repeated neuroimaging and ophthalmologic examinations to detect tumor growth or visual deterioration. Thirty-three children (19%) were found to have OPT at a median age of 4.2 years. The median age of children who had ophthalmologic complaints was significantly lower than that of children who had no such complaints (1.9 vs 5.3 years; p < 0.001). Although eight tumors were discovered because of ophthalmologic complaints or evidence of precocious puberty, 25 children (76%) were free of symptoms at the time of diagnosis. Twenty-one children (64%) had normal ophthalmologic findings at diagnosis; six children, all with chiasmal tumors, had previously unrecognized decreased visual acuity. Only three children (9%) had evidence of either tumor growth or deteriorating vision after diagnosis; the median duration of neuroimaging follow-up was 2.4 years (range, 0.2 to 7.2 years) and of ophthalmologic examinations 3.4 years (range, 0.2 to 8.1 years). All symptomatic OPT were diagnosed before 6 years of age. We conclude that OPT rarely progress during the next few years in children with NF-1 once the OPT have been discovered. The utility of screening neuroimaging for OPT in symptom-free children with NF-1 appears very limited.

Entities:  

Mesh:

Year:  1994        PMID: 8021787     DOI: 10.1016/s0022-3476(94)70122-9

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  107 in total

1.  Optic pathway glioma: correlation of imaging findings with the presence of neurofibromatosis.

Authors:  L Kornreich; S Blaser; M Schwarz; A Shuper; T H Vishne; I J Cohen; R Faingold; S Michovitz; B Koplewitz; G Horev
Journal:  AJNR Am J Neuroradiol       Date:  2001 Nov-Dec       Impact factor: 3.825

2.  Visual pathway glioma: an erratic tumour with therapeutic dilemmas.

Authors:  A Shuper; G Horev; L Kornreich; S Michowiz; R Weitz; R Zaizov; I J Cohen
Journal:  Arch Dis Child       Date:  1997-03       Impact factor: 3.791

3.  Neurofibromatosis 1-associated optic pathway gliomas.

Authors:  Ben Shofty; Liat Ben Sira; Shlomi Constantini
Journal:  Childs Nerv Syst       Date:  2020-06-11       Impact factor: 1.475

Review 4.  A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.

Authors:  Nancy Ratner; Shyra J Miller
Journal:  Nat Rev Cancer       Date:  2015-04-16       Impact factor: 60.716

Review 5.  Pediatric surgical neuro-oncology: current best care practices and strategies.

Authors:  James T Rutka; John S Kuo
Journal:  J Neurooncol       Date:  2004 Aug-Sep       Impact factor: 4.130

6.  Neurofibromatosis-1 regulates neuroglial progenitor proliferation and glial differentiation in a brain region-specific manner.

Authors:  Da Yong Lee; Tu-Hsueh Yeh; Ryan J Emnett; Crystal R White; David H Gutmann
Journal:  Genes Dev       Date:  2010-09-28       Impact factor: 11.361

7.  Investigation of retinal nerve fiber layer thickness and ganglion cell layer-inner plexiform layer thickness in patients with optic pathway gliomas.

Authors:  Mustafa Hepokur; Ahmet Murat Sarici
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-05-12       Impact factor: 3.117

8.  Treatment of neurofibromatosis type 1.

Authors:  Caterina Sabatini; Donatella Milani; Francesca Menni; Gianluca Tadini; Susanna Esposito
Journal:  Curr Treat Options Neurol       Date:  2015-06       Impact factor: 3.598

Review 9.  Using neurofibromatosis-1 to better understand and treat pediatric low-grade glioma.

Authors:  David H Gutmann
Journal:  J Child Neurol       Date:  2008-10       Impact factor: 1.987

10.  Remission of a chiasmatic glioma in a non-NF1 patient after brief chemotherapy with vincristine and carboplatin: case report and literature review.

Authors:  Elpis Mantadakis; Maria Raissaki; Vassiliki Danilatou; Alexander Kambourakis; Eftichia Stiakaki; Maria Kalmanti
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.